Alexandra Calmy, MD, PhD

Division of Infectious Diseases, Geneva University Hospital, University of Geneva, Switzerland

Disclosure(s): Gilead Sciences: Grant/Research Support; MSD: Grant/Research Support; ViiV Healthcare: Grant/Research Support

Poster(s):

• (P-364) Efficacy and Safety by Sex Assigned at Birth After Switch to Doravirine/Islatravir (100 mg/0.25 mg) Once Daily: Week 48 Results from Two Phase 3 Randomized, Active-Controlled Studies in Adults Living with HIV-1
  Monday, October 20, 2025

  12:15 PM - 1:30 PM US ET